Ionis Pharmaceuticals Inc (NASDAQ: IONS) has reported a loss for its first fiscal quarter (ending March 31) of $-0.98 versus a loss $-0.87 for the same period a year ago. This result exceeded the consensus estimate of $-1.11 by $0.12. For the latest four quarters through March 31, E.P.S. were $-2.67 versus $-2.31 for the same period a year ago.
Recent Price Action
Ionis Pharmaceuticals Inc (NASDAQ: IONS) stock declined by -3.2% on 5/7/24. The shares closed at $40.93. Moreover, trading volume in this decline was above average at 125% of normal. The stock has performed in line with the market over the last nine months and has declined -2.5% during the last week.
Current PriceTarget Research Rating
IONS is expected to continue to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ionis Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Ionis Pharmaceuticals has a slightly negative Power Rating of 38 and a very low Appreciation Score of 2, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment